ReviewInternational journal of burns and trauma2025
Comparative risk of osteoporotic fractures with direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients: a systematic review.
Review in International journal of burns and trauma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is increasingly prevalent in the elderly population and is associated with an elevated risk of osteoporotic fractures. This systematic review aimed to compare the risk of osteoporotic fractures between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), particularly warfarin, in patients with AF and to conduct head-to-head comparisons among different DOACs. We systematically searched literature published between January 2020 and October 2024 across multiple scientific databases. The included studies focused on adult patients with AF taking anticoagulants with fracture outcomes. We extracted and synthesized data on the fracture risk across different anticoagulant types. Our analysis revealed that DOACs, particularly rivaroxaban and apixaban, were associated with a lower fracture risk in AF patients than VKAs. Among the DOACs, apixaban appeared to have the most favorable profile for reducing hip fracture risk. Multiple studies have confirmed that DOACs are associated with decreased vertebral fracture risk compared to warfarin, with risk reductions ranging from 18-32% depending on the specific DOAC. DOACs appear to offer a safer alternative to VKAs in terms of fracture risk in patients with atrial fibrillation. This protective effect may be attributed to their lack of interference with vitamin K-dependent bone metabolism. Although evidence suggests that apixaban and rivaroxaban may have superior bone-protective profiles among DOACs, further research is needed to establish definitive comparisons between individual DOACs and elucidate their protective mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.